FDA tags Gilead's entospletinib an Orphan Drug for GvHD

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

The FDA designates Gilead Sciences' (NASDAQ:GILD) entospletinib (GS-9973) an Orphan Drug for the treatment of Graft-versus-Host Disease (GvHD).

Entospletinib is a selective inhibitor of an enzyme called spleen tyrosine kinase which plays a role in the pathology of B-cell lymphoid malignancies.

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

Subscribe for full text news in your inbox